Brought to you by 
Breath Therapeutics spins off from Pari Pharma, raises €43.5mm in Series A round
13 Sep 2017
Executive Summary
Concurrent with its spin-off from Pari Pharma GMBH, Breath Therapeutics Holding BV (inhaled therapies for pulmonary orphan indications) raised €43.5mm ($46mm) in its Series A financing co-led by GIMV and Sofinnova Partners, which were joined by Gilde Healthcare.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
-
Medical Devices
- Monitoring Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Breath Therapeutics spins off from Pari Pharma, raises €43.5mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice